Organoselenium Derivatives in Drug Discovery
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (15 April 2023) | Viewed by 1907
Special Issue Editor
Interests: medicinal chemistry; organic synthesis; enzyme inhibitors; antiproliferative agents; anti-Alzheimer's agents; polyphenols; iminosugars; coumarins; steroids; antioxidants; organoselenium compounds
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Organoselenium compounds have received great attention from the scientific community, particularly since the isolation of selenoproteins, which act as natural antioxidant machinery against oxidative stress, due to the presence of selenium in their active site. This led to the consideration of selenium as an essential trace element.
Since then, a plethora of selenium-containing compounds have been prepared in many different areas, with quite diverse purposes, like building blocks in synthetic organic chemistry, structural organic chemistry, catalysis, medicinal chemistry or materials science, among others.
Regarding their biological properties, organoselenium compounds emerged as very promising pharmacophores in the development of potential new drugs; in this context, the selenoheterocyclic derivative ebselen (benzo[d][1,2]-selenazol-3(2H)-one) is currently under clinical trial evaluation.
Besides the very well-known antioxidant properties, which allow them to efficiently scavenge reactive oxygen and nitrogen species (ROS, RNS), or to mimic selenoproteins, like glutathione peroxidases (GPx), a countless number of relevant pharmacological properties have been found. Numerous organoselenium compounds exhibit antiproliferative properties, which might enable the development of new cytotoxic agents or adjuvants. Additionally, anti-inflammatory, antinociceptive, antiviral, or anti-Alzheimer’s activities have also been reported.
Therefore, the aim of this Special Issue is to provide an overview of recent pharmacological research of organoselenium compounds.
Dr. Óscar López
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- organoselenium derivatives
- oxidative stress
- anticancer
- anti-Alzheimer’s agents
- enzymatic inhibitors
- anti-inflammatory
